Alcresta Therapeutics, the makers of RELiZORB, is dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with serious diseases, such as cystic fibrosis and digestive cancers.

The company uses its proprietary technology platform to support a pipeline of products, with an initial focus on fat malabsorption addressed by RELiZORB, a first-of-its-kind digestive enzyme cartridge.

Based in Massachusetts, Alcresta Therapeutics has made significant scientific and development advances in its product pipeline and is developing a portfolio of point-of-care enzyme-based products designed to address the need for improved nutritional care in a number of medical conditions.

Learn more about Alcresta Therapeutics at the company’s website.


This information is intended for
US healthcare professionals


You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.